Navigation Links
Dr. Michael Brownlee receives JDRF Rumbough Award for Scientific Excellence
Date:5/19/2008

May 19, 2008 (BRONX, NY) Michael Brownlee, M.D., the Anita and Jack Saltz Professor of Diabetes Research at Albert Einstein College of Medicine of Yeshiva University, has been selected by the Juvenile Diabetes Research Foundation (JDRF) to receive the prestigious David Rumbough Award for Scientific Excellence. The award recognizes researchers for their outstanding achievement and commitment to diabetes research. Actress Dina Merrill established this award in 1974 in honor of her late son, David.

Upon the presentation of the award, Ms. Merrill noted, I am honored to join with you tonight in the presentation of the David Rumbough Award for Scientific Excellence, which was established in honor of my late, beloved son, David. He would have been very pleased to know that research towards a cure is progressing rapidly and improving the lives of so many. Keep up the good work.

Dr. Brownlee is one of the most respected and influential scientists in his field and is noted for his innovative approach to understanding the biochemical basis of diabetic complications. He is internationally recognized for his research including his discovery of a novel molecular pathway linking hyperglycemia to diabetic retinopathy, a complication of the disease.

His propensity for creative exploration has also led to other notable contributions to the field of knowledge in understanding type 1 diabetes and its complications. For example, through his studies, Dr. Brownlee has established that the four seemingly independent biochemical pathways found to contribute to hyperglycemia-induced damage in type 1 diabetes polyol pathway activation, advanced glycation endproduct (AGE) formation, protein kinase C (PKC), and hexosamine pathway activation all arise from a single hyperglycemia-induced process that is initiated by overproduction of toxic free radicals produced by the cells mitochondria. He also has demonstrated that normalizing free-radical levels inhibits the pathways through which cell damage occurs. And, his research of benfotiamine, a synthetic derivative of the dietary supplement thiamine (vitamin B1), found that it blocked all major pathways of hyperglycemic damage, and that it blocked formation of structural lesions in the retinas of long-term diabetic animals. His current studies include clinical trials of benfotiamine.

Dr. Brownlee also is the Director of the JDRF International Center for Diabetic Complications Research at Einstein. All of the projects in this Center share an overriding aim: to develop innovative, highly effective therapies for preventing the development and progression of retinopathy, nephropathy, neuropathy, and atherosclerosis in type 1 patients.

In 2006, JDRF awarded Dr. Brownlee with its Scholar Award. His contributions to the field have also been extensively recognized through his receipt of other prestigious awards, including the 2005 Naomi Berrie Award for Outstanding Achievement in Diabetes Research from Columbia University Medical Center; the 2004 Banting Medal, the highest scientific award of the American Diabetes Association; the 2004 Davis Award from the Childrens Diabetes Foundation; the 2003 Claude Bernard Medal, the highest scientific honor given by the European Association for the Study of Diabetes; and the 1993 Outstanding Scientific Achievement Award, presented by the American Diabetes Association.

In addition to Dr. Brownlee, a 2008 JDRF Rumbough Award also was presented to Dr. Michael German, of the University of California San Francisco.


'/>"/>

Contact: Karen Gardner
kgardner@aecom.yu.edu
718-430-3101
Albert Einstein College of Medicine
Source:Eurekalert

Related medicine news :

1. Michael A. Sandler, MD, Installed as President of Michigan State Medical Society
2. Mylan Appoints Michael J. Monroe Senior Vice President for Global Public Affairs
3. Michael E. DeBakey Receives Congressional Gold Medal
4. Consumers Research Council of America Names Pediatrician Michael Y. Wu, MD, MBA as One of Americas Top Pediatricians
5. Childhood Obesity Expert Dr. William Dietz Featured at the 2nd Annual Michael & Susan Dell Lectureship in Child Health
6. Michael D. Farley Appointed Chief Operating Officer of Lupus Foundation of America, Inc.
7. Michael J. Fox Foundation Commits Up to $2 Million to Improve Drug Delivery for Parkinsons Disease
8. Michael A. Giaquinto to Join Greenhill as a Managing Director
9. STERIS Corporation Names Michael J. Tokich Chief Financial Officer
10. Cardinal Health Names Michael C. Kaufmann to Lead Pharmaceutical Segment
11. Cultivating the Smart Patient: Author and RealAge Founder Michael F. Roizen, MD to Present Keynote at URAC Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... CA (PRWEB) , ... February 21, 2017 , ... Doctors ... , CA, directed by Dr. Kendell Mendonca , to its growing network of ... compensation injuries including injuries stemming from car accidents such as whiplash, back pain, neck ...
(Date:2/21/2017)... ... , ... Ray Insurance Agencies, a Dallas area firm providing asset protection services ... a six month charity event aimed at raising local support and donations that will ... the deadliest diseases in America; more than 7.5 million people die from cancer related ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... the further expansion of its eHealth App xChange™, providing clinical researchers more ... Bioclinica’s extensive and growing eHealth platform. Applications that enable patient-centered clinical trials ...
(Date:2/21/2017)... ... February 21, 2017 , ... HIMSS is the ... care demonstration spanned multiple health information systems including OpenEMR, EMRDirect, and Epic. ... have no Health Information Exchange outside of faxing. Medal’s innovative technology “meets providers ...
(Date:2/21/2017)... (PRWEB) , ... February 21, 2017 , ... ... coffee house-caliber protein espresso drinks, announced its products are now available for purchase ... Coffee Protein Drink Mix has become popular among health-conscious consumers who love coffee ...
Breaking Medicine News(10 mins):
(Date:2/21/2017)... 2017 Sangamo Therapeutics, Inc. (Nasdaq: SGMO), the ... company will release its fourth quarter and full year ... February 28, 2017. The press release will be followed ... will be open to the public via telephone and ... its financial results and provide a business update. ...
(Date:2/21/2017)... , Feb. 21, 2017 ... announced a new imaging solution that connects Lexmark multifunction ... one of the world,s leading scanning and indexing software ... Connector enables hospitals to use a Lexmark MFP at ... the Solarity workflow, helping facilities reach HIMSS Stage ...
(Date:2/21/2017)... 2017 EMS Find, Inc. (OTCQB: EMSF), ... platforms with focus on e-commerce, health care and ... a worldwide, on-revocable and renewable Software Licensing and ... company serving healthcare organizations and facilities throughout ... EpicMD,s platform eliminates the need for health ...
Breaking Medicine Technology: